Press Releases

	Jerusalem, Israel, July 27, 2010 Teva Reports Strong Second Quarter 2010 Results
	Jerusalem, July 23, 2010 Teva Comments on Generic Lovenox® Approval
	Jerusalem, Israel, July 16, 2010 Teva Provides Update on Generic Protonix® Litigation
	Jerusalem, Israel, July 7, 2010 Teva to Report Second Quarter 2010 Financial Results on July 27, 2010
	Jerusalem, July 1, 2010 Teva Introduces First Generic Effexor XR® Capsules in the United States; Awarded 180-Day Period of Marketing Exclusivity
	Jerusalem, Israel, June 29, 2010 Teva Announces Approval of Generic Effexor XR®
	Jerusalem, June 28, 2010 Teva Announces Launch of Generic ARIMIDEX®
	Jerusalem, June 18, 2010 Teva Announces Completion of $2.5 Billion of Senior Notes Offering Secures Financing for ratiopharm Acquisition
	Jerusalem, June 15, 2010 Teva Announces Pricing of $2.5 Billion of Senior Notes Secures Financing for ratiopharm Acquisition
	Jerusalem, June 4, 2010 Teva Announces Positive Results From a Study Assessing a New Formulation of COPAXONE®
	Jerusalem, June 2, 2010 Teva Announces Launch of Generic Differin®
	Jerusalem, June 1, 2010 Teva Announces Launch of Generic Yaz® Tablets
	Jerusalem, Israel, May 31, 2010 Teva to Present at the UBS Global Specialty Pharmaceuticals Conference
	Jerusalem, May 25, 2010 Teva to Present at the 2010 Citi Investment Research Global Health Care Conference
	Jerusalem, May 25, 2010 Teva Announces Launch of Generic Valtrex®
	Jerusalem, May 19, 2010 Teva Announces Launch and Shipment of Generic Lipitor® Tablets in Canada
	Jerusalem, May 18, 2010 Teva Reaches Settlement Agreement With AstraZeneca Regarding Generic Entocort® EC Capsules
	Jerusalem, Israel, May 17, 2010 Teva Provides Update on Talampanel for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
	Jerusalem, May 14, 2010 Teva Announces Tentative Approval of Generic Sensipar®
	Jerusalem, May 11, 2010 Teva To Present At The Bank Of America Merrill Lynch Health Care Conference
	Jerusalem, May 7, 2010 Teva Provides Update on Las Vegas Trial
	Jerusalem, Israel, May 4, 2010 Teva Reports First Quarter 2010 Results
	Jerusalem, Israel, May 3, 2010 Teva To Present At The Deutsche Bank 35th Annual Health Care Conference
	Jerusalem, April 28, 2010 Teva Announces Launch of Generic Flomax®
	Jerusalem, April 23, 2010 Teva Provides Update on Generic Protonix® Litigation
	Jerusalem, Israel, April 19, 2010 ADAGIO Analysis Demonstrates that the Natural Progression of Clinical Symptoms in Parkinson's Disease May Be Slower in Earlier Stages
	Jerusalem, Israel and Lund, Sweden, April 15, 2010 New Data Suggest Oral Laquinimod May Confer Neuroprotection in Addition to Immunomodulation in the Treatment of Multiple Sclerosis
	Jerusalem, Israel, April 15, 2010 Teva to Report First Quarter 2010 Financial Results on May 4, 2010
	Jerusalem, Israel, April 12, 2010 Teva Announces Copaxone® Reaches One Million Patient Years Of Experience In The Treatment Of Multiple Sclerosis
	Jerusalem, April 7, 2010 Teva to Present New Data on Multiple Sclerosis and Parkinson's Disease at the 62nd American Academy of Neurology Annual Meeting
	Jerusalem, April 7, 2010 Teva Announces Final Approval of Generic Hyzaar® and Cozaar®
	Jerusalem, April 1, 2010 Teva Provides Update on Gemzar® Litigation
	Jerusalem, April 1, 2010 Teva Receives Favorable Court Decision Regarding Seasonique®
	Jerusalem, April 1, 2010 Teva Settles Generic Eloxatin Litigation
	Jerusalem, March 25, 2010 Teva Announces Tentative Approval of Generic Argatroban® Injection
	Jerusalem, March 18, 2010 Teva Invites Public to Listen to Webcast of Investor Meeting
	Jerusalem, Israel, March 18, 2010 Teva To Acquire ratiopharm
	Jerusalem, March 17, 2010 Teva Provides Update on Generic Temodar®
	Jerusalem, Israel, March 9, 2010 Teva Announces the Appointment of Dr. Philip Frost As Chairman of Its Board of Directors
	Jerusalem, Israel, March 5, 2010 Teva to Present at the Cowen and Company 30th Annual Healthcare Conference
	Jerusalem, March 2, 2010 Teva Announces Favorable Court Ruling in Generic Hyzaar® and Cozaar® Litigation
	Jerusalem, Israel, February 25, 2010 Copaxone® 15-Year Study in Multiple Sclerosis Patients Demonstrates Robust Long-Term Efficacy and Safety
	Jersulaem, Israel, February 22, 2010 Teva To Present At The 14th Annual Israeli Equities Conference
	Jerusalem, Israel, February 16, 2010 Teva Reports Record Full Year 2009 And Fourth Quarter Results
	Jerusalem, February 15, 2010 Teva Announces Agreement on Famvir® Patent Challenge
	Jerusalem, Israel, February 14, 2010 Eli Hurvitz Takes a Three Week Medical Leave of Absence
	Jerusalem, Israel, Lund, Sweden, February 8, 2010 Teva Acquires Marketing Rights For Oral Laquinimod In The Nordic And Baltic Regions
	Jerusalem, February 5, 2010 Teva Announces Settlement in Principle regarding Certain Drug Pricing Lawsuits
	Jerusalem, February 2, 2010 Teva Announces FDA Accepts BLA for XM02
	Jerusalem, Israel, January 26, 2010 Teva Receives Favorable Court Decision Regarding Generic Temodar®
	Jerusalem, Israel, January 22, 2010 Court of Appeals Affirms Favorable Decision Regarding Generic Prevacid® SoluTab
	Jerusalem, Israel, January 21, 2010 Teva Announces Tentative Approval of Generic Femara® Tablets
	Jerusalem, Israel, January 19, 2010 Teva to Donate Medicine to Haiti Earthquake Relief Effort
	Jerusalem, Israel, January 19, 2010 Teva to Report Fourth Quarter and Full Year 2009 Financial Results on February 16, 2010
	Jerusalem, Israel, January 14, 2010 Moody's Upgrades Teva Rating to A3
	Jerusalem, Israel, January 8, 2010 Teva To Present At The 28th Annual J.P. Morgan Healthcare Conference
	Jerusalem, Israel, January 7, 2010 Teva Presents Strategic Plan to Deliver Strong Growth
	Jerusalem, Israel, January 7, 2010 Teva Announces Settlement Agreements With AstraZeneca Regarding Generic Prilosec® and Nexium®
	Jerusalem, Israel, January 4, 2010 Teva to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference